Daytrana (Methylphenidate) Patent Expiration, LOE Window & CMS Spending

Daytrana (Methylphenidate) by Noven: Off-Patent Genericized (AB Competition), 1 AB generics, $5.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNoven
FDA Application & PathwayN021514 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$5.0M
2024 Medicare Part D Spend$144K
2024 Medicaid Spend$4.8M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 16.8% 2-yr change)